Product Description
Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist. Capsaicin is a chili pepper extract with analgesic properties. Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin)
Mechanisms of Action: TRPV1 Agonist, GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: NeurogesX
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neuropathic Pain
Phase 2: Animal Hypersensitivity|Asthma|Chronic Cough|Chronic Pain|Environmental Hypersensitivity|Evans Syndrome|Fish Hypersensitivity|Food Hypersensitivity|Labor Pain
Phase 1: Healthy Volunteers|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06809569 |
MK-0000-420 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2023-12-15 |
2025-02-06 |
Primary Endpoints|Treatments |
|
NCT04125563 |
NCT04125563 | P2 |
Active, not recruiting |
Environmental Hypersensitivity|Neuropathic Pain|Chronic Pain|Labor Pain|Animal Hypersensitivity|Asthma|Food Hypersensitivity|Fish Hypersensitivity|Chronic Cough|Evans Syndrome |
2025-12-30 |
2024-11-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2004-004670-88 |
Acute Hernia Study | P2 |
Completed |
Unknown |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2024-514934-19-00 |
AV001 | P3 |
Active, not recruiting |
Neuropathic Pain |
2025-08-30 |
2025-05-02 |
Treatments |
|
NCT04967664 |
RISE | P3 |
Completed |
Neuropathic Pain |
2025-03-07 |
21% |
2025-09-03 |
Primary Endpoints|Study Completion Date |
2021-001409-64 |
2021-001409-64 | P3 |
Active, not recruiting |
Neuropathic Pain |
2024-01-10 |
2025-05-06 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/05/2026 |
News Article |
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm |
|
02/04/2026 |
News Article |
Diabetic Neuropathy Treatment Market Set to Grow from USD 4.71 Billion in 2024 to USD 9.93 Billion by 2034 |
|
01/19/2026 |
News Article |
Citrus Burn Examined (2026 REPORT) Is CitrusBurn Legit? Research-Backed Investigation of Ingredients, Mechanisms & Safety |
|
01/15/2026 |
News Article |
aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement |